Treating Early Esophageal Cancer With ESD or Surgery

Early esophageal cancer can sometimes be removed through the lumen rather than treated with an esophagectomy. Endoscopic submucosal dissection (ESD) offers precise removal of selected lesions, while surgery remains essential when cancer has a meaningful risk of lymph-node spread or cannot be completely excised endoscopically.

The choice depends on tumor depth, size, histologic type, differentiation, lymphovascular invasion, and the patient’s general health. High-resolution endoscopy, image-enhanced assessment, and careful staging are central to making a safe decision.

The educational program associated with the ISDE 2021 World Congress for Esophageal Diseases highlighted the importance of research, multidisciplinary care, and evidence-based treatment planning. These principles remain relevant when comparing local endoscopic therapy with major surgical treatment.

What ESD involves

ESD removes an early malignant lesion in one piece by making a mucosal incision and dissecting beneath the tumor through the submucosal layer. En bloc removal allows the pathologist to assess lateral and deep margins accurately, which is particularly valuable for larger or irregular lesions.

Compared with conventional endoscopic mucosal resection, ESD can provide better control of extensive, scarred, or non-lifting lesions. It avoids an external incision and preserves the esophagus, but it requires advanced operator expertise and careful management of bleeding, perforation, and post-treatment narrowing.

When endoscopic treatment is appropriate

Endoscopic therapy is most suitable for superficial tumors confined to the mucosa, especially when there is a low probability of lymphatic or vascular spread. Early squamous cell carcinoma and selected Barrett’s-associated adenocarcinomas may qualify when they meet accepted curative criteria.

A resection specimen may show unexpected high-risk features. Deep submucosal invasion, lymphovascular invasion, poor differentiation, involved margins, or an unfavorable tumor pattern can prompt additional treatment, including esophagectomy or systemic therapy. An apparently successful ESD is therefore only part of the treatment pathway.

When surgery has an advantage

Esophagectomy removes the primary tumor and regional lymph nodes, providing pathological staging beyond what an endoscopic specimen can offer. This matters because even a small tumor can spread to lymph nodes when it invades deeply into the submucosa or displays aggressive biological features.

Surgery may be recommended for T1b disease with substantial nodal risk, incomplete endoscopic removal, multifocal disease, or anatomy that prevents safe and complete ESD. However, esophagectomy is a major operation. Pulmonary complications, anastomotic leakage, nutritional problems, reflux, and prolonged recovery must be weighed against its oncologic benefits.

Comparing cancer control and recovery

For properly selected mucosal cancers, endoscopic resection can achieve excellent long-term disease control while avoiding the functional consequences of esophagectomy. Patients often return to normal activity sooner and retain more of their natural swallowing anatomy.

These benefits do not mean ESD is universally equivalent to surgery. Evidence is strongest in carefully defined early-stage groups treated at experienced centers. Local recurrence or a separate lesion can also develop, particularly in patients with extensive Barrett’s mucosa or field changes associated with squamous cancer.

The role of pathology and surveillance

Pathology determines whether ESD was curative. Reports should address tumor size, depth of invasion, differentiation, lymphovascular invasion, ulceration when relevant, and the status of horizontal and vertical margins. A clear margin alone does not eliminate the possibility of nodal disease.

Surveillance typically includes follow-up endoscopy and management of treatment-related strictures. Patients treated for Barrett’s-related neoplasia may need ongoing attention to the remaining abnormal mucosa, while those with squamous lesions may require assessment of the entire upper aerodigestive tract according to local protocols.

Making the decision with a specialist team

A multidisciplinary review can bring together an advanced endoscopist, esophageal surgeon, pathologist, radiologist, oncologist, and nutrition specialist. Staging may include endoscopic ultrasound, cross-sectional imaging, and selected functional or metabolic studies, although the exact workup varies by tumor type and clinical setting.

Patient factors also influence the decision. Age, lung and heart function, nutritional status, previous operations, swallowing symptoms, and personal priorities should be considered alongside tumor biology. A second pathology review or referral to a high-volume center can be valuable when the treatment choice is uncertain.

Practical points for treatment planning

• Confirm the lesion’s depth and borders with expert endoscopic evaluation.
• Match the proposed treatment to squamous cell carcinoma or adenocarcinoma biology.
• Review the complete ESD specimen before declaring endoscopic cure.
• Discuss esophagectomy promptly when high-risk pathology is identified.
• Establish a structured surveillance and nutritional follow-up plan.

Selecting ESD or surgery for early esophageal cancer requires more than comparing procedure size or recovery time. The safest strategy is the one that provides adequate cancer control while limiting unnecessary harm. Use current staging evidence, expert pathology, and multidisciplinary judgment to develop an individualized plan for each patient.